Observation of the compatibility of stimulated Raman histology with pathology workflow and genome sequencing

International audienceWe show that human samples imaged with stimulated Raman histology (SRH) can be successfully used in a typical pathology workflow including hematoxylin and eosin staining (HE), immunohistochemistry, and genome sequencing. We provide a morphological comparison of SRH images with the gold standard HE and HES (HE and saffron) staining over three normal tissues from various organs (liver, kidney, and ileum) and two tumoral brain samples (metastatic adenocarcinoma and glioblastoma). Most importantly, we show that a sample imaged with SRH has a comparable microscopic appearance as a control sample (that was not imaged by SRH) including protein expression evaluated by immunohistochemistry as well as similar genetic alterations evaluated by genome sequencing. This suggests that SRH can provide a direct diagnosis without material preparation nor consumptio

High-dose-rate vs. low-dose-rate interstitial brachytherapy boost for anal canal cancers

International audienceThe purpose of this study was to analyze and compare clinical outcomes of low-dose-rate (LDR) and high-dose-rate (HDR) interstitial brachytherapy boost (ISBT) after EBRT or radio chemotherapy for the treatment of anal canal cancers

The impact of brachytherapy boost for anal canal cancers in the era of de-escalation treatments

International audiencePurpose: To analyze clinical outcomes of high-dose-rate (HDR) interstitial brachytherapy boost (ISBT) after external beam radiation therapy (EBRT) or chemoradiotherapy (CRT) for the treatment of anal canal cancers (ACC).Methods and materials: A total of 78 patients with ACC were treated at our institution by ISBT. Local Control (LC), disease-free survival (DFS), overall survival (OS), colostomy-free survival (CFS) and toxicity rates were analyzed.Results: With a median followup (FU) of 59.8 months (95% CI [55.8-64.2]), six (7.7%) local recurrences with 2 patients (2.6%) having persistent disease at 3 months were observed. The 5-year rate of LC for the entire population was 92% [83-96%]. The 5-year DFS rate was 86% [76-93%]. The 5-year OS was 96% [88-99%]. In the univariate analysis, chemotherapy was significantly associated with morbidity grade ≥2. Late digestive toxicity grade ≥3 was reported in 8.9% patients, 1 patient underwent colostomy due to toxicity. The 5-year CFS rate was 88% [79-94%].Conclusions: HDR interstitial brachytherapy boost provide excellent rates of tumor control and colostomy-free survival with a favorable profile of GI toxicity. Continence in anal cancer survivors is a challenge and the boost technique must be discussed in a multidisciplinary approach as part of de-escalation treatments